Entrada Therapeutics, Inc. (TRDA) insider buying and selling
There were no open-market insider purchases or sales at Entrada Therapeutics, Inc. (TRDA) in the last 90 days. Over the last 12 months, 1 insider bought $29K of the stock, led by Bernhardt G Zeiher (Director), who bought $29K on May 20, 2026; 2 insiders sold $629K, of which $629K was scheduled or tax-related.
This is the public summary. Create a free account to see TRDA’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.
Unlock TRDARecent open-market insider trades
Trades by the same insider within a week are shown as one line.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Bernhardt G Zeiher Director | Open market purchase | 5,000 | $5.86 | $29K |
Scheduled and tax-related sales
Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Natarajan Sethuraman President | 10b5-1 sale | 25,907 | $15.39 | $399K | |
| Nathan J Dowden COO | 10b5-1 sale | 15,000 | $15.33 | $230K |
What the TRDA insider trades really mean
The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Entrada Therapeutics, Inc. and every other stock we track:
TRDA's AI Signal score
One score from six weighted factors, with the full breakdown behind it, so you can see whether the buying is a real signal.
Unlock with a free accountEvery trade on the price chart
See each TRDA insider purchase and sale plotted on the chart, with the gain or loss on every one since.
Unlock with a free accountInsider track records
Is Bernhardt G Zeiher worth following? See their grade, win rate and average return on past purchases.
Unlock with a free accountAnalysts vs insiders
The consensus rating and price target next to the insider activity. Do the analysts agree?
Unlock with a free accountTrading windows
See when TRDA insiders are likely free to trade, shaded on the chart, so you know when to expect new filings.
Unlock with a free accountAlerts the moment they file
Get an email, Slack or in-app alert when a TRDA insider files, plus alerts for cluster buying.
Unlock with a free accountPlus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.
Questions about TRDA insider trading
Who bought Entrada Therapeutics, Inc. (TRDA) stock recently?
Insiders who bought Entrada Therapeutics, Inc. stock on the open market in the last 12 months: Bernhardt G Zeiher ($29K). The most recent purchase was reported on May 20, 2026.
Are insiders buying or selling TRDA?
Over the last 12 months insiders were net buyers of TRDA on discretionary trades: $29K bought against $0 sold (scheduled and tax-related sales excluded).
What is a sell-to-cover or 10b5-1 sale?
A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.
Where does this data come from?
Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.
Other stocks with recent insider buying
- MAIR · Madison Air Solutions Corp$219.6M bought by insiders, last 90 days
- BRVE · Braveheart Bio, Inc.$39.5M bought by insiders, last 90 days
- PAMT · PAMT CORP$31.2M bought by insiders, last 90 days
- AUGO · Aura Minerals Inc.$22.7M bought by insiders, last 90 days
- ET · Energy Transfer$21.5M bought by insiders, last 90 days
- AAT · American Assets Trust, Inc.$18.2M bought by insiders, last 90 days
Create a free account and open its chart, score and alerts.
How to read this page
Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.
Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.